The inhibition of thymidine phosphorylase can reverse acquired 5FU-resistance in gastric cancer cells.

Publication Year: 2018

DOI:
10.1007/s10120-018-0881-3

PMCID:
PMC6476841

PMID:
30276573

Journal Information

Full Title: Gastric Cancer

Abbreviation: Gastric Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
2/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest Kazuhiro Y. has received grants and personal fees and honoraria from Taiho Pharmaceutical Co., Ltd., and had a consultant or advisory relationship with Taiho Pharmaceutical Co., Ltd. Outside of the submitted work, Kazuhiro Y. has received grants and personal fees from Pfizer Inc., Chugai Pharmaceutical Co., Ltd., and Yakult Honsha Co., Ltd.; grants from Bristol-Myers Squibb and Kyowa Hakko Kirin Co., Ltd.; honoraria from Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., and Yakult Honsha Co., Ltd., and had a consultant or advisory relationship with La Roche, Ltd. All of the remaining authors declare that they have no conflicts of interest."

Evidence found in paper:

"This work was supported by Grants-in-Aid for Scientific Research (C) (Grant no. 16K10496) from the Ministry of Education, Culture, Sports, Science and Technology and Taiho Pharmaceutical Co., Ltd. Human rights statementAll procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.: Animal studiesThis article does not contain any studies with human or animal subjects performed by any of the authors.: Conflict of interestKazuhiro Y. has received grants and personal fees and honoraria from Taiho Pharmaceutical Co., Ltd., and had a consultant or advisory relationship with Taiho Pharmaceutical Co., Ltd. Outside of the submitted work, Kazuhiro Y. has received grants and personal fees from Pfizer Inc., Chugai Pharmaceutical Co., Ltd., and Yakult Honsha Co., Ltd.; grants from Bristol-Myers Squibb and Kyowa Hakko Kirin Co., Ltd.; honoraria from Pfizer Inc., Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., and Yakult Honsha Co., Ltd., and had a consultant or advisory relationship with La Roche, Ltd. All of the remaining authors declare that they have no conflicts of interest."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025